RxDoctor Payments DataLook up a doctor →

Joggy George, MD

Cardiovascular Disease · Houston, TXNPI 1558556001

Payments from drug & device makers

$634,377in general payments, 2019–2025

Across 1,201 payments — averaging $528.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$258K
  • Procyrion, Inc.$145K
  • AstraZeneca$60K
  • Lexicon Pharmaceuticals, Inc.$59K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$30K
  • Pfizer$25K
  • plus $56K from 54 others
$373in research payments, 2019–2025

Across 3 payments — averaging $124.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$373

What the payments were for

  • Consulting fees$1,6131%
  • Speaking & faculty fees$167,49073%
  • Travel & lodging$23,17310%
  • Food & beverage$38,58517%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.43$258,110
Procyrion, Inc.3$145,436
AstraZeneca105$60,271
Lexicon Pharmaceuticals, Inc.90$58,761
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)71$30,368
Pfizer82$24,883
Abiomed87$22,071
Novartis63$9,229
Abbott119$6,425
Medtronic(2 entities)54$4,394
Boston Scientific19$1,415
Actelion Pharmaceuticals US, Inc.41$1,116
Inari Medical, Inc.14$1,094
Johnson & Johnson49$1,016
Amgen51$967
Impulse Dynamics (USA) Inc.11$882
E.r. Squibb & Sons, L.L.C.45$787
Cardiovascular Systems Inc.12$781
Novo Nordisk30$716
Merck35$713
Cvrx, Inc.8$439
Bayer19$435
Chiesi USA, Inc.22$403
Esperion Therapeutics, Inc.21$346
Boehringer Ingelheim17$316
Penumbra, Inc.2$285
Atricure, Inc.2$272
Saranas, Inc.2$183
Alnylam Pharmaceuticals Inc.6$159
Bridgebio Pharma, Inc.4$147
Bolton Medical Inc1$138
Edwards Lifesciences1$134
Biotronik Inc.4$125
Scpharmaceuticals Inc.6$115
Akcea Therapeutics, Inc.1$110
Angiodynamics, Inc.5$106
Daiichi Sankyo Inc.5$105
Heartflow, Inc.4$103
Sanofi-aventis U.S. LLC5$85
ZOLL Circulation Inc1$84
Kiniksa Pharmaceuticals International, PLC3$76
Irhythm Technologies, Inc.5$74
Siemens Medical Solutions USA, Inc.1$67
Endologix LLC2$63
Kestra Medical Technology Services, Inc.3$56
Cleerly, Inc.2$54
Tactile Systems Technology Inc3$53
Kiniksa Pharmaceuticals, Ltd.2$44
United Therapeutics Corporation2$40
Arbor Pharmaceuticals, Inc.2$32
Surmodics, Inc.1$27
Inspire Medical Systems, Inc.1$26
Astellas Pharma US Inc1$21
W. L. Gore & Associates, Inc.1$20
Lundbeck LLC1$20
Teleflex LLC1$20
Itamar Medical Inc1$20
Takeda Pharmaceuticals U.S.A., Inc.1$19
Baxter Healthcare1$19
Amarin Pharma, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$634,377 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$889,632
Medicare patients
727
Services billed
5,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis31$936,436
OpsumitMacitentan26$379,782
EntrestoSacubitril/Valsartan194$296,749
FarxigaDapagliflozin Propanediol231$219,411
EliquisApixaban154$180,477
JardianceEmpagliflozin104$125,929
Repatha SureclickEvolocumab62$54,433
XareltoRivaroxaban42$42,927
OzempicSemaglutide27$32,806
CorlanorIvabradine Hcl20$15,745
DapagliflozinDapagliflozin Propanediol18$10,431
Amlodipine-ValsartanAmlodipine Besylate/Valsartan155$10,391
Sirolimus24$9,706
Eplerenone103$9,661
Valsartan310$9,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$24,883$1,116,913185 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,116$379,78226 claims
NovartisEntresto$9,229$296,749194 claims
AstraZenecaFarxiga$60,271$219,411231 claims
Boehringer IngelheimJardiance, Tradjenta$316$133,239116 claims
Johnson & JohnsonXarelto$1,016$42,92742 claims
Novo NordiskOzempic$716$32,80627 claims
AmgenCorlanor$967$15,74520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →